Payers won’t let these products break the bank.
Ira Studin, PhD
Advertisement
Articles by Ira Studin, PhD
Conditions require a disciplined approach to drug pricing.
Shift focus in orphan and ultra-orphan messaging to clinical benefit.
Supporting health plan clinical preparation and financial modeling.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Novartis’ $23 Billion Manufacturing Investment Anchors Industry Shift Toward US Onshoring
2
Trade & Channel Strategies 2025: The $405 Billion Patent Cliff Demands Partnership and Adaptive Market Access Strategies
3
The Key to Connecting with Patients: Pharma's Market Access Transformation
4
Why Specialty Drugs Dominate Spending, and the Frontline Roles Shaping Patient Access
5
